Roche: FDA approves diagnostic test for lung cancer
(CercleFinance.com) - Roche has won US approval on Thursday to market a cobas EGFR mutation test as a companion diagnostic test with AstraZeneca's lung cancer drug, Iressa.
A companion diagnostic test provides information for the effective use of a corresponding therapeutic product, the Swiss group said.
In this particular case, patients diagnosed with non-small cell lung cancer who test positive for defined mutations of the epidermal growth factor receptor (EGFR) gene can benefit from tyrosine kinase inhibitor (TKI) therapies.
The cobas EGFR Mutation Test v2 is currently the only FDA-approved diagnostic test for non-small cell lung cancer using liquid biopsy, using a simple blood draw.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A companion diagnostic test provides information for the effective use of a corresponding therapeutic product, the Swiss group said.
In this particular case, patients diagnosed with non-small cell lung cancer who test positive for defined mutations of the epidermal growth factor receptor (EGFR) gene can benefit from tyrosine kinase inhibitor (TKI) therapies.
The cobas EGFR Mutation Test v2 is currently the only FDA-approved diagnostic test for non-small cell lung cancer using liquid biopsy, using a simple blood draw.
Copyright (c) 2018 CercleFinance.com. All rights reserved.